On 2 February 2021 we were delighted to co-host alongside BDO, our first question time webinar aimed at growth stage companies. During the question and answer event our panel provided their expert advice for maximising value throughout the typical lifecycle of an innovative, forward-looking business, providing a practical insight into the key commercial and intellectual property issues that businesses should consider to capitalise on value at each stage.

Topical issues covered in the webinar included:

  • Barriers to fundraising
  • Attracting investors
  • Securing & leveraging IP valuations
  • Maximising cash repayments from HMRC

If you have any IP questions following the webinar, please do not hesitate to reach out to Venner Shipley partner, Anton Hutter at ahutter@vennershipley.co.uk.

Panel:

Anton Hutter, Venner Shipley

UK & European patent attorney and IP specialist. He heads up Venner Shipley’s Guildford office and specialises in biotechnology and pharmaceuticals. Anton advises start-up companies and SMEs, particularly in the life sciences sector, where building a valuable patent portfolio is vital for their future investment.

Kevin Voller, BDO

Head of Innovation Taxes for BDO’s South East practice. He has 20 years’ experience of providing strategic advice to growing, entrepreneurial companies to maximise tax reliefs and significantly improve cash flow.

Christopher Pett, SETsquared

Digital Innovation Sector Lead at the SETsquared Scale Up Programme. Responsible for supporting high-growth start-ups to secure venture capital investment and R&D funding to build and commercialise breakthrough technology solutions.

Chaired by:

Will Lovegrove, University of Surrey

Head of Technology Transfer & interim co-Director of Innovation Strategy at University of Surrey. Will is responsible for managing and growing the pipeline of university-wide commercialisation opportunities.

Speaker(s)

  • Anton Hutter

    Anton is a UK and European patent attorney, and works in our Guildford office. He is a partner in our Chemical and Life Sciences team.